Published in

Faculdade de Medicina / USP, Clinics, 12(66), p. 2141-2149, 2011

DOI: 10.1590/s1807-59322011001200022

Links

Tools

Export citation

Search in Google Scholar

Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

Journal article published in 2011 by Vassilios Fanos, Michele Pusceddu, Angelica Dessì ORCID, Maria Antonietta Marcialis
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.